Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 · mRESVIA (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
FDA approves Moderna’s mRNA RSV vaccine for older adults
May 31, 2024 · CNN — The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the name...
Moderna Receives Health Canada Approval for RSV Vaccine for …
6 days ago · mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and Qatar CAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canada has approved mRESVIA™ (Respiratory ...
Moderna Receives European Commission Approval for RSV Vaccine …
Aug 23, 2024 · CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mRESVIA ® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by …
Introducing the World’s First mRNA Vaccine Against RSV - Moderna
mRESVIA is Moderna’s mRNA vaccine approved in the U.S. to protect adults aged 60 years and over from severe lower respiratory tract disease (LRTD) caused by respiratory syncytial virus, or RSV, infection.
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older …
Dec 13, 2023 · The mRNA-1345 vaccine (Moderna) uses the same preF antigen and is based on the mRNA vaccine platform that was previously shown to be effective in addressing the worldwide burden of severe...
Investigational mRNA Vaccines & Respiratory Syncytial Virus - Moderna
Jan 17, 2023 · Today we announced positive top-line data from our pivotal Phase 3 study of mRNA-1345, our investigational vaccine candidate against respiratory syncytial virus (RSV), in older adults. RSV is a common seasonal virus that can …
FDA approves mRNA-based RSV vaccine - Nature
Jun 7, 2024 · The FDA has approved Moderna’s mRNA-based respiratory syncytial virus (RSV) vaccine mRNA-1345 (mRESVIA) to protect adults aged 60 years and older from lower respiratory tract disease....
mRNA vaccine effective against RSV respiratory disease - Nature
Feb 15, 2023 · Moderna has announced topline results for its mRNA-based vaccine against respiratory syncytial virus (RSV) infection in adults 60 years of age and older. mRNA-1345 targets the RSV fusion...
FDA Approves Moderna RSV Vaccine, an mRNA Alternative to ... - MedCity News
May 31, 2024 · Moderna’s mResvia is now the third FDA-approved RSV vaccine and the first one based on mRNA technology. It will compete for market share against RSV shots from GSK and Pfizer that won their...